# Palacký University Olomouc

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/palacky-university-olomouc/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 84.5 |
| Citations | 2,286,777 |
| City | Olomouc |
| Country | CZ |
| Description | Palacký University Olomouc is a research organisation in Olomouc, CZ. OpenAlex records 37,988 works and 2,286,777 citations for it. 6,873 researchers list it as their most recent affiliation. |
| Homepage | https://www.upol.cz |
| OpenAlex ID | https://openalex.org/I70703428 |
| Region | Olomoucký |
| Researchers | 6,873 |
| ROR ID | https://ror.org/04qxnmv42 |
| Type | education |
| Works | 37,988 |

## University papers

- [Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renal-cell-carcinoma/)
- [Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-monotherapy-for-previously-treated-advanced-gastric-or-gastro/)
- [Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-or-everolimus-for-advanced-renal-cell-carcinoma/)
- [Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial](https://scholariq.org/papers/efficacy-and-safety-of-trastuzumab-deruxtecan-in-patients-with-her2-expressing/)
- [Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-for-her2/)
- [Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case–control studies](https://scholariq.org/papers/cigarette-smoking-and-lung-cancer-relative-risk-estimates-for-the-major/)
- [Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study](https://scholariq.org/papers/efficacy-and-safety-of-tisotumab-vedotin-in-previously-treated-recurrent-or/)
- [Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial](https://scholariq.org/papers/pictilisib-for-oestrogen-receptor-positive-aromatase-inhibitor-resistant/)
- [Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-placebo-as-post-nephrectomy-adjuvant-therapy-for-clear-cell/)
- [Multiple ADH genes are associated with upper aerodigestive cancers](https://scholariq.org/papers/multiple-adh-genes-are-associated-with-upper-aerodigestive-cancers/)
- [Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-sunitinib-as-first-line-treatment-of/)

## University top topics

Showing 8 of 22.

- [Quantum Information and Cryptography](https://scholariq.org/topics/quantum-information-and-cryptography/)
- [Particle physics theoretical and experimental studies](https://scholariq.org/topics/particle-physics-theoretical-and-experimental-studies/)
- [High-Energy Particle Collisions Research](https://scholariq.org/topics/high-energy-particle-collisions-research/)
- [Plant Molecular Biology Research](https://scholariq.org/topics/plant-molecular-biology-research/)
- [Quantum Mechanics and Applications](https://scholariq.org/topics/quantum-mechanics-and-applications/)
- [Advanced Algebra and Logic](https://scholariq.org/topics/advanced-algebra-and-logic/)
- [Rough Sets and Fuzzy Logic](https://scholariq.org/topics/rough-sets-and-fuzzy-logic/)
- [Particle Detector Development and Performance](https://scholariq.org/topics/particle-detector-development-and-performance/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.